Institutional shares held 44.7 Million
64.8K calls
562K puts
Total value of holdings $218M
$316K calls
$2.75M puts
Market Cap $277M
56,561,500 Shares Out.
Institutional ownership 79.0%
# of Institutions 157


Latest Institutional Activity in VNDA

Top Purchases

Q2 2025
Farther Finance Advisors, LLC Shares Held: 1.66K ($8.12K)
Q2 2025
Fifth Third Bancorp Shares Held: 153 ($748)
Q2 2025
Gamma Investing LLC Shares Held: 63 ($308)
Q1 2025
Millennium Management LLC Shares Held: 2.14M ($10.5M)
Q1 2025
Nuveen, LLC Shares Held: 441K ($2.15M)

Top Sells

Q2 2025
Public Employees Retirement System Of Ohio Shares Held: 32.9K ($161K)
Q1 2025
Morgan Stanley Shares Held: 917K ($4.48M)
Q1 2025
Schroder Investment Management Group Shares Held: 666K ($3.26M)
Q1 2025
Renaissance Technologies LLC Shares Held: 3.57M ($17.4M)
Q1 2025
Jacobs Levy Equity Management, Inc Shares Held: 274K ($1.34M)

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.


Insider Transactions at VNDA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.35M Shares
From 12 Insiders
Grant, award, or other acquisition 1.25M shares
Open market or private purchase 102K shares
Sell / Disposition
207K Shares
From 7 Insiders
Payment of exercise price or tax liability 192K shares
Open market or private sale 14.3K shares

Track Institutional and Insider Activities on VNDA

Follow Vanda Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VNDA shares.

Notify only if

Insider Trading

Get notified when an Vanda Pharmaceuticals Inc. insider buys or sells VNDA shares.

Notify only if

News

Receive news related to Vanda Pharmaceuticals Inc.

Track Activities on VNDA